Clinical Trial Update: Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial investigates the combination of atezolizumab and bevacizumab in several rare solid tumors, with the study currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Squamous Cell Carcinoma
• Appendiceal Adenocarcinoma
• Cervical Squamous Cell Carcinoma
• Merkel Cell Carcinoma
• Nasopharyngeal Carcinoma
• Pancreatic Neuroendocrine Tumor
• Penile Squamous Cell Carcinoma
• Vulvar Squamous Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Tecentriq (atezolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING